how much weight can you lose with retatrutide produces up to 30.3% loss in Phase 3 trial Retatrutide vs. Other Weight Loss

Cardiovascular outcome trials of the incretin-based therapies: what do we know so far

Research has found that orlistat can help 37% of people lose 5% of their body weight after 12 weeks of treatment

The most common issues are gastrointestinal: Nausea Affects 2040% of users, usually worst in the first 48 weeks and improves with dose titration Diarrhea or constipation Reported in 1020% of users Reduced appetite This is partly the mechanism of action, but some users report it as uncomfortably intense early on Injection site reactions Mild redness or itching (injectable drugs only) Fatigue and dizziness Usually related to reduced caloric intake in early weeks Serious side effects are rare but include pancreatitis (very rare), gallbladder problems (more common with rapid weight loss), and thyroid C-cell concerns (a theoretical risk from animal studies not confirmed in humans)

In the body, IGF-1 plays a central role in recovery, tissue repair, and muscle growth